Immunoglobulin replacement in hematological malignancies: a focus on evidence, alternatives, dosing strategy, and cessation rule

References

• Parikh SA, Leis JF, Chaffee KG, et al. Hypogammaglobulinemia in newly diagnosed chronic lymphocytic leukemia: natural history, clinical correlates, and outcomes. Cancer. 2015;121(17):2883–2891.
   PubMed Web of Science ®Google Scholar
• Sørrig R, Klausen TW, Salomo M, t al. Immunoparesis in newly diagnosed multiple myeloma patients: effects on overall survival and progression free survival in the danish population. PLoS One. 2017;12(12):e0188988.
   PubMed Web of Science ®Google Scholar
• Singh N, Mott SL, McCarthy AN, et al. Prevalence and the impact of hypogammaglobulinemia in newly diagnosed, untreated diffuse large B cell lymphoma. Blood. 2019;134(1):1604–1604.
   Google Scholar
• Na IK, Buckland M, Agostini C, et al. Current clinical practice and challenges in the management of secondary immunodeficiency in hematological malignancies. Eur J Haematol. 2019;102(6):447–456.
   PubMed Web of Science ®Google Scholar
• Nørgaard M, Larsson H, Pedersen G, et al. Risk of bacteraemia and mortality in patients with haematological malignancies. Clin Microbiol Infect. 2006;12(3):217–223.
   PubMed Web of Science ®Google Scholar
• Gale RP, Chapel HM, Bunch C, et al. Intravenous immunoglobulin for the prevention of infection in chronic lymphocytic leukemia. A randomized, controlled clinical trial. N Engl J Med. 1988;319(14):902–907.
   PubMed Web of Science ®Google Scholar
• Prevot J, Jolles S. Global immunoglobulin supply: steaming towards the iceberg? Curr Opin Allergy Clin Immunol. 2020;20(6):557–564.
   PubMed Web of Science ®Google Scholar
• Stiehm ER. Adverse effects of human immunoglobulin therapy. Transfus Med Rev. 2013;27(3):171–178.
   PubMed Web of Science ®Google Scholar
• Späth PJ, Granata G, La Marra F, et al. On the dark side of therapies with immunoglobulin concentrates: the adverse events. Front Immunol. 2015;6:11.
   PubMed Web of Science ®Google Scholar
• Committee MSA. In: Health Do, editor. Application No. 1565 – review of immunoglobulin use for acquired hypogammaglobulinaemia secondary to haematological malignancies and haemopoietic stem cell transplantation. Australia: Committee MSA; 2019.
   Google Scholar
• Monleón Bonet C, Waser N, Cheng K, et al. A systematic literature review of the effects of immunoglobulin replacement therapy on the burden of secondary immunodeficiency diseases associated with hematological malignancies and stem cell transplants. Expert Rev Clin Immunol. 2020;16(9):911–921.
   PubMed Web of Science ®Google Scholar
• Ohmoto A, Fuji S, Shultes KC, et al. Controversies about immunoglobulin replacement therapy in HSCT recipients with hypogammaglobulinemia. Bone Marrow Transplant. 2022;57(6):874–880.
   PubMed Web of Science ®Google Scholar
• Authority NB. Criteria for the clinical use of intravenous immunoglobulin in Australia. Lyneham, Australia: National Blood Authority; 2012.
   Google Scholar
• Agency EM. Guideline on the clinical investigation of human normal immunoglobulin for intravenous administration (IVIg) 2021. [cited 2022 12-07]. Available from: https://www.ema.europa.eu/en/clinical-investigation-humannormal-immunoglobulin-intravenous-administration-ivig#current-effective-versionsection
   Google Scholar
• Otani IM, Lehman HK, Jongco AM, et al. Practical guidance for the diagnosis and management of secondary hypogammaglobulinemia: a work group report of the AAAAI primary immunodeficiency and altered immune response committees. J Allergy Clin Immunol. 2022;149(5):1525–1560.
   PubMed Web of Science ®Google Scholar
• Ye C, Chen W, Gao Q, et al. Secondary immunodeficiency and hypogammaglobulinemia with IgG levels of <5 g/L in patients with multiple myeloma: a retrospective study between 2012 and 2020 at a university hospital in China. Med Sci Monit. 2021;27:e930241.
   PubMed Web of Science ®Google Scholar
• Chapel HM, Lee M, Hargreaves R, et al. Randomised trial of intravenous immunoglobulin as prophylaxis against infection in Plateau-phase multiple myeloma. The UK group for immunoglobulin replacement therapy in multiple myeloma. Lancet. 1994;343(8905):1059–1063.
   PubMed Web of Science ®Google Scholar
• Khalafallah A, Maiwald M, Cox A, et al. Effect of immunoglobulin therapy on the rate of infections in multiple myeloma patients undergoing autologous stem cell transplantation or treated with immunomodulatory agents. Mediterr J Hematol Infect Dis. 2010;2(1):e2010005.
   PubMedGoogle Scholar
• Musto P, Brugiatelli M, Carotenuto M. Prophylaxis against infections with intravenous immunoglobulins in multiple myeloma. Br J Haematol. 1995;89(4):945–946.
   PubMed Web of Science ®Google Scholar
• Raanani P, Gafter-Gvili A, Paul M, et al. Immunoglobulin prophylaxis in chronic lymphocytic leukemia and multiple myeloma: systematic review and Meta-analysis. Leuk Lymphoma. 2009;50(5):764–772.
   PubMed Web of Science ®Google Scholar
• Offidani M, Corvatta L, Polloni C, et al. Infectious complications in patients with multiple myeloma treated with new drug combinations containing thalidomide. Leuk Lymphoma. 2011;52(5):776–785.
   PubMedGoogle Scholar
• Chakraborty R, Majhail NS. Treatment and disease-related complications in multiple myeloma: Implications for survivorship. Am J Hematol. 2020;95(6):672–690.
   PubMed Web of Science ®Google Scholar
• Lancman G, Lozada K, Athar N, et al. Efficacy of intravenous immunoglobulin for preventing infections in patients with multiple myeloma. Clin Lymphoma Myeloma Leuk. 2021;21(5):e470–e476.
   PubMed Web of Science ®Google Scholar
• Vacca A, Melaccio A, Sportelli A, et al. Subcutaneous immunoglobulins in patients with multiple myeloma and secondary hypogammaglobulinemia: a randomized trial. Clin Immunol. 2018;191:110–115.
   PubMed Web of Science ®Google Scholar
• Vitkon R, Netanely D, Levi S, et al. Daratumumab in combination with proteasome inhibitors, rapidly decreases polyclonal immunoglobulins and increases infection risk among relapsed multiple myeloma patients: a single center retrospective study. Ther Adv Hematol. 2021;12:20406207211035272–20406207211035272.
   Web of Science ®Google Scholar
• Lancman G, Sastow D, Aslanova M, et al. Effect of Intravenous Immunoglobulin on Infections in Multiple Myeloma (MM) Patients Receiving Daratumumab. Blood. 2020 Nov 5;136(Supplement 1):6–7.
   Google Scholar
• Paul Y, Aguirre LE, Basher F, et al. Hypogammaglobulinemia and its implications in patients treated with daratumumab: a single institution experience. Blood. 2019;134(1):3131–3131.
   Google Scholar
• Dimopoulos MA, Oriol A, Nahi H, et al. Daratumumab, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2016;375(14):1319–1331.
   PubMed Web of Science ®Google Scholar
• Patel SY, Carbone J, Jolles S. The expanding field of secondary antibody deficiency: causes, diagnosis, and management. Front Immunol. 2019;10:33–33.
   PubMed Web of Science ®Google Scholar
• Mikulska M, Lanini S, Gudiol C, et al. ESCMID study group for infections in compromised hosts (ESGICH) consensus document on the safety of targeted and biological therapies: an infectious diseases perspective (agents targeting lymphoid cells surface antigens [I]: CD19, CD20 and CD52). Clin Microbiol Infect. 2018;24(2):S71–S82.
   PubMed Web of Science ®Google Scholar
• Fischer T, Ni A, Bantilan KS, et al. The impact of anti-CD20-based therapy on hypogammaglobulinemia in patients with follicular lymphoma. Leuk Lymphoma. 2022;63(3):573–582.
   PubMed Web of Science ®Google Scholar
• Goede V, Fischer K, Busch R, et al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med. 2014;370(12):1101–1110.
   PubMed Web of Science ®Google Scholar
• Hirata A, Miyashita K, Tanaka T, et al. Serum immunoglobulin G as a discriminator of infection in follicular lymphoma patients undergoing chemotherapy with bendamustine in combination with rituximab. Hematology. 2022;27(1):384–395.
   PubMed Web of Science ®Google Scholar
• Suzuki M, Koyama D, Ikeda S, et al. Serum IgG and lymphocyte counts are useful for the early detection of infection in patients receiving bendamustine-rituximab therapy. J Clin Exp Hematop. 2022;62:91–98.
   PubMed Web of Science ®Google Scholar
• De Angelis F, Tosti ME, Capria S, et al. Risk of secondary hypogammaglobulinaemia after rituximab and fludarabine in indolent non-Hodgkin lymphomas: a retrospective cohort study. Leuk Res. 2015;39(12):1382–1388.
   PubMed Web of Science ®Google Scholar
• Jennifer ML, Elisa Z, Christina AB, et al. Immune reconstitution and associated infections following axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma. Haematologica. 2020;106(4):978–986.
   Web of Science ®Google Scholar
• Paolo S, Ankur V, Sherry A, et al. Hematopoietic recovery and immune reconstitution after axicabtagene ciloleucel in patients with large B-cell lymphoma. Haematologica. 2020;106(10):2667–2672.
   Web of Science ®Google Scholar
• Losonczy H, Nagy Á, Kosztolányi S, et al. [Correlations between secondary hypogammaglobulinaemia, infections and mortality and the need for preventive immunoglobulin replacement in patients with chronic lymphoid leukaemia]. Orv Hetil. 2019;160(38):1487–1494.
   PubMed Web of Science ®Google Scholar
• Benbrahim O, Viallard JF, Choquet S, et al. The use of octagam and gammanorm in immunodeficiency associated with hematological malignancies: a prospective study from 21 french hematology departments. Hematology. 2019;24(1):173–182.
   PubMed Web of Science ®Google Scholar
• Griffiths H, Brennan V, Lea J, et al. Crossover study of immunoglobulin replacement therapy in patients with low-grade B-cell tumors. Blood. 1989;73(2):366–368.
   PubMed Web of Science ®Google Scholar
• Boughton BJ, Jackson N, Lim S, et al. Randomized trial of intravenous immunoglobulin prophylaxis for patients with chronic lymphocytic leukaemia and secondary hypogammaglobulinaemia. Clin Lab Haematol. 2008;17(1):75–80.
   Google Scholar
• Byrd JC, Furman RR, Coutre SE, et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med. 2013;369(1):32–42.
   PubMed Web of Science ®Google Scholar
• Sun C, Tian X, Lee YS, et al. Partial reconstitution of humoral immunity and fewer infections in patients with chronic lymphocytic leukemia treated with ibrutinib. Blood. 2015;126(19):2213–2219.
   PubMed Web of Science ®Google Scholar
• Wo S, Levavi H, Mascarenhas J, et al. Immunoglobulin repletion during blinatumomab therapy does not reduce the rate of secondary hypogammaglobulinemia and associated infectious risk. Blood Res. 2022;57(2):135–143.
   PubMed Web of Science ®Google Scholar
• Zugmaier G, Topp MS, Alekar S, et al. Long-term follow-up of serum immunoglobulin levels in blinatumomab-treated patients with minimal residual disease-positive B-precursor acute lymphoblastic leukemia. Blood Cancer J. 2014;4(9):244.
   PubMedGoogle Scholar
• McQuilten Z, Weinkove R, Crispin P, et al. Rational: a randomised controlled feasibility trial comparing prophylactic immunoglobulin with antibiotics in patients with acquired hypogammaglobulinemia secondary to haematological malignancies. EHA Library. 2021;324690. https://library.ehaweb.org/eha/2021/eha2021-virtual-congress/324690/zoe.mcquilten.rational.a.randomised.controlled.feasibility.trial.comparing.html?f=menu%3D6%2Abrowseby%3D8%2Asortby%3D2%2Amedia%3D3%2Ace_id%3D2035%2Aot_id%3D25566
   Google Scholar
• Smits BM, Kleine Budde I, de Vries E, et al. Immunoglobulin replacement therapy versus antibiotic prophylaxis as treatment for incomplete primary antibody deficiency. J Clin Immunol. 2021;41(2):382–392.
   PubMed Web of Science ®Google Scholar
• Wong J, Wood EM, Crispin P, et al. Managing hypogammaglobulinaemia secondary to haematological malignancies in Australia and New Zealand: a clinician survey. Intern Med J. 2019;49(3):358–363.
   PubMed Web of Science ®Google Scholar
• Sánchez-Ramón S, Dhalla F, Chapel H. Challenges in the role of gammaglobulin replacement therapy and vaccination strategies for hematological malignancy. Front Immunol. 2016;7:317.
   PubMed Web of Science ®Google Scholar
• Teh JSK, Coussement J, Neoh ZCF, et al. Immunogenicity of COVID-19 vaccines in patients with hematologic malignancies: a systematic review and Meta-analysis. Blood Adv. 2022;6(7):2014–2034.
   PubMed Web of Science ®Google Scholar
• Walti CS, Krantz EM, Maalouf J, et al. Antibodies against vaccine-preventable infections after CAR-T cell therapy for B cell malignancies. JCI Insight. 2021;6:e146743.
   PubMed Web of Science ®Google Scholar
• Svensson T, Kättström M, Hammarlund Y, et al. Pneumococcal conjugate vaccine triggers a better immune response than pneumococcal polysaccharide vaccine in patients with chronic lymphocytic leukemia a randomized study by the Swedish CLL group. Vaccine. 2018;36(25):3701–3707.
   PubMed Web of Science ®Google Scholar
• Gribabis DA, Panayiotidis P, Boussiotis VA, et al. Influenza virus vaccine in B-cell chronic lymphocytic leukaemia patients. Acta Haematol. 1994;91(3):115–118.
   PubMed Web of Science ®Google Scholar
• Bucalossi A, Marotta G, Galieni P, et al. Immunological response to influenza virus vaccine in B-Cell chronic lymphocytic leukaemia patients. Acta Haematol. 1995;93(1):56–56.
   PubMed Web of Science ®Google Scholar
• Sinisalo M, Vilpo J, Itälä M, et al. Antibody response to 7-valent conjugated pneumococcal vaccine in patients with chronic lymphocytic leukaemia. Vaccine. 2007;26(1):82–87.
   PubMed Web of Science ®Google Scholar
• Koleba T, Ensom MHH. Pharmacokinetics of intravenous immunoglobulin: a systematic review. Pharmacotherapy. 2006;26(6):813–827.
   PubMed Web of Science ®Google Scholar
• Stump SE, Schepers AJ, Jones AR, et al. Comparison of Weight-Based dosing strategies for intravenous immunoglobulin in patients with hematologic malignancies. Pharmacotherapy. 2017;37(12):1530–1536.
   PubMed Web of Science ®Google Scholar
• Grindeland JW, Grindeland CJ, Moen C, et al. Outcomes associated with standardized ideal body weight dosing of intravenous immune globulin in hospitalized patients: a multicenter study. Ann Pharmacother. 2020;54(3):205–212.
   PubMed Web of Science ®Google Scholar
• Figgins BS, Aitken SL, Whited LK. Optimization of intravenous immune globulin use at a comprehensive cancer center. Am J Health Syst Pharm. 2019;76(4):S102–S106.
   PubMedGoogle Scholar
• Hodkinson JP. Considerations for dosing immunoglobulin in obese patients. Clin Exp Immunol. 2017;188(3):353–362.
   PubMed Web of Science ®Google Scholar
• Jolles S, Michallet M, Agostini C, et al. Treating secondary antibody deficiency in patients with haematological malignancy: European expert consensus. Eur J Haematol. 2021;106(4):439–449.
   PubMed Web of Science ®Google Scholar
• Goddard S, Diwakar L, Hughes D, et al. Impact of stopping long-term immunoglobulin therapy in patients with secondary antibody deficiency due to haematological disease. Br J Haematol. 2021;193(2):e12–e15.
   PubMed Web of Science ®Google Scholar
• McNulty CMG, Joshi AY. Low class switched memory B cells predicts the need for continued need for replacement immunoglobulin therapy post rituximab use and adequate numeric B cell reconstitution. J Allergy Clin Immunol. 2018;141(2):AB83.
   Web of Science ®Google Scholar
• Patel V, Cameron DW, Cowan J. Immunoglobulin replacement therapy discontinuation in patients with antibody deficiency secondary to hematological malignancy. Hematol Oncol. 2021;39(4):584–588.
   PubMed Web of Science ®Google Scholar